Jed Hubbs

This inventor holds 9 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Neurocycle Therapeutics, Inc., Other. Active years: 2010-2026.

USPTO Granted Patents = 9 (Patent Applications = 5)

% Patents Active = 88.9

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 5(Granted Patents)

Company Filing History:

4 out of 2,405

Merck Sharp + Dohme Corp.

patents

4 out of 4

Neurocycle Therapeutics, Inc.

patents

1 out of 834,307

Other

patents

Years Active: 2010-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617794 - GABAA positive allosteric modulator compounds, methods of making, and uses thereof (2026-05-05),

2. 12134619 - Crystalline salts or co-crystals of 2',6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile with p-toluenesulofonic acid as GABAA positive allosteric modulators (2024-11-05),

3. 11571421 - GABAA positive allosteric modulator compounds for treatment of itch and/or dermatitis (2023-02-07),

4. 11542263 - Crystalline salts or co-crystals of 2',6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b] [1,2,4]triazin-7-yl]biphenyl-2-carbonitrile with phosphoric acid as GABAA positive allosteric modulators (2023-01-03),

5. 8609897 - Trifluoromethylsulfonamide gamma secretase inhibitor (2013-12-17),

6. 8420622 - Silylated piperidine derivatives (2013-04-16),

7. 8389547 - Piperidines and related compounds for the treatment of Alzheimer's disease (2013-03-05),

8. 8168658 - Inhibitors of histone deacetylase (2012-05-01),

9. 7772238 - Benzothiophene hydroxamic acid derivatives (2010-08-10),

Title: The Innovative Contributions of Jed Hubbs

Introduction

Jed Hubbs is a notable inventor based in Cambridge, MA (US), recognized for his significant contributions to the field of pharmacology. With a total of 9 patents to his name, Hubbs has made strides in developing compounds that enhance GABAA receptor activity, which is crucial for various therapeutic applications.

Latest Patents

Hubbs' latest patents include innovative GABAA positive allosteric modulator compounds. One of his notable inventions describes polymorphs comprising 2',6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b][1,2,4]tri-azin-7-yl]biphenyl-2-carbonitrile (TPA023B) or salts thereof. This patent outlines a crystalline polymorphic salt or co-crystal of TPA023B with phosphoric acid, as well as with sulfuric acid. Additionally, he has developed crystalline salts or co-crystals of TPA023B with p-toluenesulfonic acid, further expanding the potential applications of these compounds.

Career Highlights

Throughout his career, Hubbs has worked with prominent companies such as Neurocycle Therapeutics, Inc. and Merck Sharp & Dohme Corp. His work in these organizations has allowed him to collaborate on groundbreaking research and development projects that push the boundaries of current medical science.

Collaborations

Hubbs has collaborated with talented individuals in his field, including Matthew Toczko and Thomas Allen Miller. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Jed Hubbs stands out as an influential inventor whose work in pharmacology has led to significant advancements in GABAA receptor modulation. His innovative patents and collaborations reflect his commitment to improving therapeutic options in medicine.